Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
van den Elskamp, IJ; Boden, B; Dattola, V; Knol, DL; Filippi, M; Kappos, L; Fazekas, F; Wagner, K; Pohl, C; Sandbrink, R; Polman, CH; Uitdehaag, BMJ; Barkhof, F.
Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis.
Neuroradiology. 2010; 52(10):875-881
Doi: 10.1007/s00234-009-0645-1
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Fazekas Franz
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Cerebral atrophy is a compound measure of the neurodegenerative component of multiple sclerosis (MS) and a conceivable outcome measure for clinical trials monitoring the effect of neuroprotective agents. In this study, we evaluate the rate of cerebral atrophy in a 6-month period, investigate the predictive and explanatory value of other magnetic resonance imaging (MRI) measures in relation to cerebral atrophy, and determine sample sizes for future short-term clinical trials using cerebral atrophy as primary outcome measure. One hundred thirty-five relapsing-remitting multiple sclerosis patients underwent six monthly MRI scans from which the percentage brain volume change (PBVC) and the number and volume of gadolinium (Gd)-enhancing lesions, T2 lesions, and persistent black holes (PBH) were determined. By means of multiple linear regression analysis, the relationship between focal MRI variables and PBVC was assessed. Sample size calculations were performed for all patients and subgroups selected for enhancement or a high T2 lesion load at baseline. A significant atrophy occurred over 6 months (PBVC = -0.33%, SE = 0.061, p < 0.0001). The number of baseline T2 lesions (p = 0.024), the on-study Gd-enhancing lesion volume (p = 0.044), and the number of on-study PBHs (p = 0.003) were associated with an increased rate of atrophy. For a 50% decrease in rate of atrophy, the sample size calculations showed that approximately 283 patients per arm are required in an unselected sampled population and 185 patients per arm are required in a selected population. Within a 6-month period, significant atrophy can be detected and on-study associations of PBVC and PBHs emphasizes axonal loss to be a driving mechanism. Application as primary outcome measure in short-term clinical trials with feasible sample size requires a potent drug to obtain sufficient power.
- Find related publications in this database (using NLM MeSH Indexing)
- Adjuvants, Immunologic - therapeutic use
- Adult -
- Atrophy - drug therapy
- Brain - drug effects
- Feasibility Studies -
- Female -
- Humans -
- Interferon-beta - therapeutic use
- Longitudinal Studies -
- Magnetic Resonance Imaging - methods
- Male -
- Multiple Sclerosis - drug therapy
- Outcome Assessment (Health Care) - methods
- Prognosis -
- Reproducibility of Results -
- Sensitivity and Specificity -
- Treatment Outcome -
- Find related publications in this database (Keywords)
- Multiple sclerosis
- Cerebral atrophy
- SIENA
- Sample size